Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis
The reduction and removal of user fees for essential care services have recently become a key instrument to advance universal health coverage in sub-Saharan Africa, but no evidence exists on its cost-effectiveness. We aimed to address this gap by estimating the cost-effectiveness of 2 user-fee exemption interventions in Burkina Faso between 2007 and 2015: the national 80% user-fee reduction policy for delivery care services and the user-fee removal pilot (ie, the complete [100%] user-fee removal for delivery care) in the Sahel region. (Source: Value in Health)
Source: Value in Health - January 17, 2020 Category: International Medicine & Public Health Authors: Hoa Thi Nguyen, Aleksandra Torbica, Stephan Brenner, Jo ël Arthur Kiendrébéogo, Ludovic Tapsoba, Valéry Ridde, Manuela De Allegri Source Type: research

Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts ’ Perspectives
In diseases where there is a large subjective component, such as celiac disease (CD), patient reported-outcomes (PRO) endpoints are highly relevant. However, there is a gap in knowledge about which PRO endpoints and instruments should be used for clinical trials for treatment of celiac disease. (Source: Value in Health)
Source: Value in Health - January 13, 2020 Category: International Medicine & Public Health Authors: Sarah Clifford, Aliki Joanna Taylor, Michele Gerber, Jacob Devine, Margaret Cho, Rebecca Walker, Ioanna Stefani, Skylar Fidel, Jennifer Drahos, Daniel A. Leffler Source Type: research

Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs
To assess whether using surrogate versus patient-relevant endpoints in pivotal trials of cancer drugs was associated with health technology assessment recommendations in England (National Institute for Health and Care Excellence [NICE]) and Canada (Canadian Agency for Drugs and Technologies in Health [CADTH]). (Source: Value in Health)
Source: Value in Health - January 13, 2020 Category: International Medicine & Public Health Authors: Ashlyn Pinto, Huseyin Naci, Emilie Neez, Elias Mossialos Source Type: research

Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations
Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or procedures, which are known as HTA practices. (Source: Value in Health)
Source: Value in Health - January 1, 2020 Category: International Medicine & Public Health Authors: Rick A. Vreman, Aukje K. Mantel-Teeuwisse, Anke M. H övels, Hubert G.M. Leufkens, Wim G. Goettsch Tags: Themed Section: HTA Around the World —Influences of Culture, Values, and Institutions Source Type: research

Table of Contents
(Source: Value in Health)
Source: Value in Health - January 1, 2020 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - January 1, 2020 Category: International Medicine & Public Health Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - January 1, 2020 Category: International Medicine & Public Health Source Type: research

Computing PROPr Utility Scores for PROMIS ® Profile Instruments
The Patient-Reported Outcomes Measurement Information System ® (PROMIS) Profile instruments measure health status on 8 PROMIS domains. The PROMIS-Preference (PROPr) score provides a preference-based summary score for health states defined by 7 PROMIS domains. The Profile and PROPr share 6 domains; PROPr has 1 unique domain (Cognitive Function–Abilities), a nd the Profile has 2 unique domains (Anxiety and Pain Intensity). We produce an equation for calculating PROPr utility scores with Profile data. (Source: Value in Health)
Source: Value in Health - December 30, 2019 Category: International Medicine & Public Health Authors: Barry Dewitt, Hawre Jalal, Janel Hanmer Source Type: research

HTA Around the World: Broadening Our Understanding of Cross-Country Differences
The attitudes toward the use of health technology assessment (HTA) in healthcare decision making vary widely between the United States and Europe and often even within Europe. Some countries use HTA extensively, others hardly at all. Some countries have independent HTA agencies; others adopt different institutional models. Some countries that conduct economic evaluations as part of HTA stress the use of quality-adjusted life-years (QALYs); others use other concepts of value. (Source: Value in Health)
Source: Value in Health - December 27, 2019 Category: International Medicine & Public Health Authors: Aleksandra Torbica Tags: Editorial Source Type: research

Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis
To find an alternative for quality-adjusted life-year (QALY) and equal value of life (EVL) measures. Despite the importance of QALY in cost-effectiveness analysis (CEA) —because it captures the effects of both life expectancy and health-related quality of life (QOL) and enables comparisons across interventions and disease areas—its potential to be discriminatory towards patients with lower QOL presents a critical challenge that has resulted in the exclusion of its use in some public decision making (eg, US Medicare) on healthcare in the United States. (Source: Value in Health)
Source: Value in Health - December 23, 2019 Category: International Medicine & Public Health Authors: Anirban Basu, Josh Carlson, David Veenstra Source Type: research

Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match?
The EQ-5D-5L valuation protocol recommends combining time trade-off (TTO) and discrete choice experiments (DCEs). DCEs that include a duration attribute (DCETTO) allow modeling on the quality-adjusted life-year scale. Because the choice sequence in a TTO can be construed as a series of DCETTO, we used data from a single TTO study to investigate the extent to which DCE values match TTO values when based on identical preferences. (Source: Value in Health)
Source: Value in Health - December 19, 2019 Category: International Medicine & Public Health Authors: Liv Ariane Augestad, Kim Rand, Nan Luo, Mathias Barra Source Type: research

A Head-On Ordinal Comparison of the Composite Time Trade-Off and the Better-Than-Dead Method
This study compares the BTD and composite time trade-off (cTTO) methods at the ordinal level. (Source: Value in Health)
Source: Value in Health - December 19, 2019 Category: International Medicine & Public Health Authors: Bram Roudijk, A. Rogier T. Donders, Peep F.M. Stalmeier Source Type: research

Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts
Our goal was to estimate the relative importance assigned to health technology assessment (HTA) criteria by stakeholders involved in the HTA process. HTA is an increasingly common framework used in the appraisal of drugs for public reimbursement. It identifies clinical, economic, social, and organizational criteria to be considered. The criteria can vary across jurisdictions and are typically appraised by multidisciplinary expert committees. Guidance on the relative weighing of criteria is often absent. (Source: Value in Health)
Source: Value in Health - December 19, 2019 Category: International Medicine & Public Health Authors: Wies ława Dominika Wranik, Michał Jakubczyk, Krzysztof Drachal Source Type: research

Formal Implementation of Cost-Effectiveness Evaluations in Japan: A  Unique Health Technology Assessment System
This article provides an overview of this new policy, which was implemented formally after a pilot program. In the fiscal year (FY) 2012, discussions on cost-effectiveness assessments were initiated in Japan. After 7 years of deliberations, a cost-effectiveness assessment was implemented formally in April  2019. (Source: Value in Health)
Source: Value in Health - December 16, 2019 Category: International Medicine & Public Health Authors: Masataka Hasegawa, Shigekazu Komoto, Takeru Shiroiwa, Takashi Fukuda Source Type: research

Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis
To investigate whether the use of economic evaluation (EE) in healthcare decision making is influenced by the social values and institutional context in a given country. (Source: Value in Health)
Source: Value in Health - December 10, 2019 Category: International Medicine & Public Health Authors: Aleksandra Torbica, Giulia Fornaro, Rosanna Tarricone, Michael Drummond Source Type: research

Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients ’ Experiences
To increase the understanding of patient-centered care (PCC) and address the need for cross-cutting quality cancer care measures that are relevant to both patients and providers. (Source: Value in Health)
Source: Value in Health - December 7, 2019 Category: International Medicine & Public Health Authors: Kerri-Anne R. Mitchell, Kelly J. Brassil, Kayo Fujimoto, Bryan M. Fellman, Laura Aubree Shay, Andrew E. Springer Source Type: research

Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis
Disease-modifying therapies (DMTs) reduce relapse rates and disability progression for relapsing multiple sclerosis (MS). Although 25% to 30% of all US patients with MS are Medicare beneficiaries, limited information exists on this population. This is the first study using national Medicare data to (1) describe characteristics of patients with MS using DMTs, (2) estimate adherence to DMTs over a 1-year and 3-year follow-up, and (3) examine factors associated with DMT adherence. (Source: Value in Health)
Source: Value in Health - December 7, 2019 Category: International Medicine & Public Health Authors: Pengxiang Li, Vrushabh P. Ladage, Joseph Berger, Salim Chahin, Mehul Jhaveri, Caroline Geremakis, Jalpa A. Doshi Source Type: research

Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary
India is a diverse land with different cultures, social norms, castes, religions, faiths, languages, politics, and a complex healthcare system. As a step to enhance healthcare, the government of India announced a move toward universal health coverage to increase accessibility and affordability of health-related services. Recently, there has been an introduction of health technology assessment (HTA) in India to help inform evidence-based decision making in cases of limited resources and budgets. Nevertheless, there are challenges related to biased decision making, an unregulated healthcare framework, and the lack of data an...
Source: Value in Health - December 6, 2019 Category: International Medicine & Public Health Authors: Shilpi Swami, Tushar Srivastava Source Type: research

Value-Based Pharmaceutical Contracts: Value for Who?
Value-based pharmaceutical contracts (VBPCs) are performance-based reimbursement agreements between healthcare payors and pharmaceutical manufacturers in which the price, amount, or nature of reimbursement is tied to value-based outcomes. VBPCs are often complex, and the nature of who benefits and in what ways can be unclear. We discuss how VBPCs compare with value-based payor –provider arrangements in terms of performance-based reimbursements and alignment of incentives. In addition, we examine how VBPCs can affect costs, clinical outcomes, and access to medications. (Source: Value in Health)
Source: Value in Health - December 5, 2019 Category: International Medicine & Public Health Authors: Joseph T. Kannarkat, Chester B. Good, Natasha Parekh Source Type: research

Socioeconomic Status of Newborns and Hospital Efficiency: Implications for Hospital Payment Methods
Studies have shown a consistent impact of socioeconomic status at birth for both mother and child; however, no study has looked at its impact on hospital efficiency and financial balance at birth, which could be major if newborns from disadvantaged families have an average length of stay (LOS) longer than other newborns. Our objective was therefore to study the association between socioeconomic status and hospital efficiency and financial balance in that population. (Source: Value in Health)
Source: Value in Health - December 4, 2019 Category: International Medicine & Public Health Authors: Morgane Michel, Corinne Alberti, Jean-Claude Carel, Karine Chevreul Source Type: research

“Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval
Changes in the regulatory context enable faster approval of transformative medicines. They also lead to health technology assessment (HTA) agencies having to make decisions with less evidence. In response, HTA agencies have also initiated forms of conditional approval. When the evidence base for a new oncology treatment leaves substantial uncertainty, the new Cancer Drugs Fund allows the National Institute for Heath and Care Excellence to give the manufacturer two options: (1) offer a low price based on conservative assumptions and obtain immediate approval ( “stick”) or (2) wait until the evidence base has fur...
Source: Value in Health - December 3, 2019 Category: International Medicine & Public Health Authors: Daniel Gladwell, Ash Bullement, Warren Cowell, Karl Patterson, Mark Strong Source Type: research

Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana
Universal healthcare coverage in low- and middle-income countries requires challenging resource allocation decisions. Health technology assessment is one important tool to support such decision making. The International Decision Support Initiative worked with the Ghanaian Ministry of Health to strengthen health technology assessment capacity building, identifying hypertension as a priority topic area for a relevant case study. (Source: Value in Health)
Source: Value in Health - December 3, 2019 Category: International Medicine & Public Health Authors: Mohamed Gad, Johanne Lord, Kalipso Chalkidou, Brian Asare, Martha Gyansa Lutterodt, Francis Ruiz Source Type: research

Table of Contents
(Source: Value in Health)
Source: Value in Health - December 1, 2019 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - December 1, 2019 Category: International Medicine & Public Health Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - December 1, 2019 Category: International Medicine & Public Health Source Type: research

A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C
Chronic hepatitis C (CHC) is among the most burdensome infectious diseases in the world. Health utilities are a valuable tool for quantifying this burden and conducting cost-utility analysis. (Source: Value in Health)
Source: Value in Health - November 28, 2019 Category: International Medicine & Public Health Authors: Yasmin A. Saeed, Arcturus Phoon, Joanna M. Bielecki, Nicholas Mitsakakis, Karen E. Bremner, Lusine Abrahamyan, Petros Pechlivanoglou, Jordan J. Feld, Murray Krahn, William W.L. Wong Tags: Systematic Literature Review Source Type: research

A Systematic Review and Meta-analysis of Health Utilities in Chronic Hepatitis C Patients
Chronic hepatitis C (CHC) is among the most burdensome infectious diseases in the world. Health utilities are a valuable tool for quantifying this burden and conducting cost-utility analysis. (Source: Value in Health)
Source: Value in Health - November 28, 2019 Category: International Medicine & Public Health Authors: Yasmin A. Saeed, Arcturus Phoon, Joanna M. Bielecki, Nicholas Mitsakakis, Karen E. Bremner, Lusine Abrahamyan, Petros Pechlivanoglou, Jordan J. Feld, Murray Krahn, William W.L. Wong Source Type: research

How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey
Debriefing questions can assess if respondents understand discrete choice experiments (DCEs) and are answering in a way consistent with theories of decision making and utility maximization. Nevertheless, there is limited literature about how often debriefing questions are included or how the results are used in health economics. The aim of this study was to conduct a survey of the frequency, type, and analysis of debriefing questions in health DCEs. (Source: Value in Health)
Source: Value in Health - November 27, 2019 Category: International Medicine & Public Health Authors: Alison M. Pearce, Brendan J. Mulhern, Verity Watson, Rosalie C. Viney Source Type: research

Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study
This prospective cohort study examines the clinical effectiveness of electronic medical record clinical decision support (EMR CDS) for opioid prescribing. (Source: Value in Health)
Source: Value in Health - November 22, 2019 Category: International Medicine & Public Health Authors: Eboni G. Price-Haywood, Jeffrey Burton, Todd Burstain, Jewel Harden-Barrios, John Lefante, Lizheng Shi, Robert N. Jamison, Alessandra Bazzano, Lydia Bazzano Source Type: research

Response to Letter to Editor Related to Methods for Measuring Multiple Medication Adherence: A Systematic Review –Report of the ISPOR Medication Adherence and Persistence Special Interest Group
We thank the editor for giving us the opportunity to respond to the letter to the editor regarding our recent publication on multiple medication adherence (MMA).1 We also thank the authors of the letter to the editor for their interest in our paper and for providing their comments, as it validates the timeliness and importance of this topic and offers the opportunity for an ardent discussion, which we believe is a hallmark of good science. At issue, in this case, is the measurement of adherence that involves polytherapeutic regimens. (Source: Value in Health)
Source: Value in Health - November 22, 2019 Category: International Medicine & Public Health Authors: Priti P. Pednekar, Tam ás Ágh, Maria Malmenäs, Amit D. Raval, Bryan M. Bennett, Bijan J. Borah, David S. Hutchins, Elizabeth Manias, Allison F. Williams, Mickaël Hiligsmann, Adina Turcu-Stiolica, John E. Zeber, Lusine Abrahamyan, Thomas J. Bunz, Andre Tags: Letter to the Editor Source Type: research

Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation
In this study of an adjuvanted RSV vaccine, we evaluated an RSV disease endpoint using a patient-reported outcome instrument (the inFLUenza Patient-Reported Outcome instrument [FLU-PRO]) and molecular testing for virologic confirmation. (Source: Value in Health)
Source: Value in Health - November 20, 2019 Category: International Medicine & Public Health Authors: Jing Yu, John H. Powers, David Vallo, Judith Falloon Source Type: research

Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Type 2 diabetes mellitus (T2DM) and associated ailments are leading economic burdens to society. Sodium glucose cotransporter-2 (SGLT2) inhibitors are recent antidiabetic medications with beneficial clinical efficacy. This meta-analysis was conducted to quantitatively pool the incremental net benefit of SGLT2 inhibitors in T2DM patients who failed metformin monotherapy. (Source: Value in Health)
Source: Value in Health - November 18, 2019 Category: International Medicine & Public Health Authors: Bhavani Shankara Bagepally, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Usa Chaikledkaew, Ammarin Thakkinstian Source Type: research

Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation
Despite potentially severe and fatal outcomes, recent studies of solid organ transplant (SOT) recipients in Europe suggest that hepatitis E virus (HEV) infection is underdiagnosed, with a prevalence of active infection of up to 4.4%. (Source: Value in Health)
Source: Value in Health - November 15, 2019 Category: International Medicine & Public Health Authors: Michael J. Ankcorn, Richard S. Tedder, John Cairns, Frank G. Sandmann Source Type: research

Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers
There is increasing interest in assessing the effects of interventions on older people, people with long-term conditions and their informal carers for use in economic evaluation. The Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer) is a measure that specifically assesses the impact of social care services on informal carers. To date, the ASCOT-Carer has not been preference-weighted. (Source: Value in Health)
Source: Value in Health - November 14, 2019 Category: International Medicine & Public Health Authors: Laurie Batchelder, Juliette Malley, Peter Burge, Hui Lu, Eirini-Christina Saloniki, Ismo Linnosmaa, Birgit Trukeschitz, Julien Forder Source Type: research

Letter to the Editor: Response to “Methods for Measuring Multiple Medication Adherence: A Systematic Review”
We appreciate the publication by Pedneakar and colleagues,1 which underlines the wide range of methods used in measuring multiple medication adherence (MMA). However, we disagree with several notions and have some suggested improvements for future reviews. (Source: Value in Health)
Source: Value in Health - November 14, 2019 Category: International Medicine & Public Health Authors: Junqiao Chen, Holly Hawes Tags: Correspondence Source Type: research

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) —innovative yet costly cholesterol-lowering agents—have been subject to substantial prior authorization (PA) requirements and low approval rates. We aimed to investigate trends in insurer approval and reasons for rejection for PCSK9i prescriptions as well as associations between patients’ demo graphic, clinical, pharmacy, payer, and PCSK9i-specific plan/coverage factors and approval. (Source: Value in Health)
Source: Value in Health - November 12, 2019 Category: International Medicine & Public Health Authors: Jalpa A. Doshi, Pengxiang Li, Justin T. Puckett, Amy R. Pettit, Swathi Raman, Michael S. Parmacek, Daniel J. Rader Source Type: research

Measuring Quality-Adjusted Life-Years When Health Fluctuates
Recurrent fluctuations in health states can occur as a result of long-term conditions with episodic symptoms or through side effects of cycles of treatment. Fluctuations and associated duration of symptoms can be predictable (eg, side effects of chemotherapy treatment) or unpredictable (eg, relapse in multiple sclerosis). Such recurrent fluctuations in health states can have an important impact on a person ’s health-related quality of life. When symptoms vary by time of day, day of the week, or during the month, it is challenging to obtain reliable health-related quality of life estimates for use in assessing cost-ef...
Source: Value in Health - November 11, 2019 Category: International Medicine & Public Health Authors: Sabina Sanghera, Joanna Coast Source Type: research

Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly
To identify how monetary incentives affect influenza vaccination uptake rate using a randomized control experiment and to subsequently design an optimal incentive program in Singapore, a high-income country with a market-based healthcare system. (Source: Value in Health)
Source: Value in Health - November 7, 2019 Category: International Medicine & Public Health Authors: Mu Yue, Yi Wang, Chng Kiat Low, Joanne Su-yin Yoong, Alex R. Cook Source Type: research

Mapping WOMAC onto the EQ-5D-5L Utility Index in Patients with Hip or Knee Osteoarthritis
To map the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) onto the EQ-5D-5L in patients with hip or knee osteoarthritis (OA). (Source: Value in Health)
Source: Value in Health - November 7, 2019 Category: International Medicine & Public Health Authors: Amaia Bilbao, Jes ús Martín-Fernández, Lidia García-Pérez, Juan Carlos Arenaza, Gloria Ariza-Cardiel, Yolanda Ramallo-Fariña, Laura Ansola Source Type: research

Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses
To conduct a systematic review of cost-utility studies of community-based services provided by pharmacists and to examine their reporting and methodological quality. (Source: Value in Health)
Source: Value in Health - November 5, 2019 Category: International Medicine & Public Health Authors: Chiranjeev Sanyal, Donald R. Husereau Source Type: research

Table of Contents
(Source: Value in Health)
Source: Value in Health - November 1, 2019 Category: International Medicine & Public Health Source Type: research

Copyright/Subscription
(Source: Value in Health)
Source: Value in Health - November 1, 2019 Category: International Medicine & Public Health Source Type: research

Editorial Board
(Source: Value in Health)
Source: Value in Health - November 1, 2019 Category: International Medicine & Public Health Source Type: research

Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example
Inappropriate use of the case-crossover design, which is efficient for examining associations between brief exposure and abrupt outcomes, in evaluating the effects of medications in the presence of exposure-time trends or persistent drug use may generate spurious associations. We compared different approaches to adjusting for these sources of bias by examining the risk of heart failure hospitalization (HFH) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors. Overall, existing evidence does not suggest a higher risk of HFH associated with DPP-4 inhibitors; however, case-crossover analyses of these medications may be ...
Source: Value in Health - October 24, 2019 Category: International Medicine & Public Health Authors: Yaa-Hui Dong, Shirley V. Wang, Joshua J. Gagne, Li-Chiu Wu, Chia-Hsuin Chang Source Type: research

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Na ïve Patients With Chronic Hepatitis C Virus
Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure rates over 8 weeks ( (Source: Value in Health)
Source: Value in Health - October 24, 2019 Category: International Medicine & Public Health Authors: Christopher G. Fawsitt, Peter Vickerman, Graham S. Cooke, STOP HCV Consortium, Nicky J. Welton Source Type: research

Cannabis and Health Research: Rapid Progress Requires Innovative Research Designs
The United States has witnessed enormous changes concerning the acceptance of medicinal and recreational cannabis use. Sixty-three percent of the US population has access to medicinal cannabis markets, which offer increasingly diverse and potent cannabis products. Considering the rapidly changing cultural, political, and legal landscape, the scientific literature does not adequately inform public policy, medical decision making, or harm reduction approaches. The goals of this paper are to (1) investigate the state of cannabis research on medical conditions commonly treated with cannabis, (2) review the barriers that have l...
Source: Value in Health - October 18, 2019 Category: International Medicine & Public Health Authors: Kent E. Hutchison, L. Cinnamon Bidwell, Jarrod M. Ellingson, Angela D. Bryan Source Type: research

Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention
For patients undergoing percutaneous coronary intervention, gene-drug associations exist relevant to first-line treatment options –antiplatelet agent, clopidogrel, and pain medication, tramadol. Knowledge of genotype information may allow for avoidance of adverse drug events during critical clinical windows. (Source: Value in Health)
Source: Value in Health - October 16, 2019 Category: International Medicine & Public Health Authors: M. Ragan Hart, Louis P. Garrison, Debra L. Doyle, Gail P. Jarvik, John Watkins, Beth Devine Source Type: research

Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development
Assessment of clinical benefit in treatment trials can be made through report by a clinician, a patient, or a nonclinician observer (eg, caregiver) or through a performance-based assessment. The US Food and Drug Administration (FDA) published a final guidance for industry for one type of clinical outcome assessment (COA) —patient-reported outcome (PRO) measures—in 2009 that described how FDA reviews PRO measures for their adequacy to support medical product–labeling claims. Many of the principles described in the PRO Guidance could be applicable to the other types of COAs, including instruments completed ...
Source: Value in Health - October 16, 2019 Category: International Medicine & Public Health Authors: Elektra J. Papadopoulos, Elizabeth Nicole Bush, Sonya Eremenco, Stephen Joel Coons Source Type: research

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward
This article provides guidance on the use of MCDA in this context. (Source: Value in Health)
Source: Value in Health - October 15, 2019 Category: International Medicine & Public Health Authors: Rob Baltussen, Kevin Marsh, Praveen Thokala, Vakaramoko Diaby, Hector Castro, Irina Cleemput, Martina Garau, Georgi Iskrov, Alireza Olyaeemanesh, Andrew Mirelman, Mohammedreza Mobinizadeh, Alec Morton, Michele Tringali, Janine van Til, Joice Valentim, Mon Tags: Methodology Source Type: research

Multicriteria Decision Analysis to Support HTA Agencies: Benefits, Limitations, and the Way Forward
This article provides guidance on the use of MCDA in this context. (Source: Value in Health)
Source: Value in Health - October 15, 2019 Category: International Medicine & Public Health Authors: Rob Baltussen, Kevin Marsh, Praveen Thokala, Vakaramoko Diaby, Hector Castro, Irina Cleemput, Martina Garau, Georgi Iskrov, Alireza Olyaeemanesh, Andrew Mirelman, M. Mobinizadeh, Alec Morton, Michele Tringali, Janine van Til, Joice Valentim, Monika Wagner Source Type: research